Generate Biomedicines offers an asymmetric bet on whether generative AI can turn protein therapeutics into an engineered, repeatable, clinically validated drug-development platform.
Overview
Generate Biomedicines is a clinical-stage generative biology company using AI and high-throughput engineering to design programmable protein therapeutics. Revenue currently comes from collaboration, licensing, research funding, and milestone arrangements with major pharma partners, while product sales remain zero. Its lead asset, GB-0895, is in Phase 3 severe asthma trials and Phase 1b COPD development. The company’s thesis rests on converting protein design from trial-and-error discovery into an engineered, scalable drug-development platform.